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ABSTRACT
Metastatic cancer cells express Membrane Type 1-Matrix Metalloproteinase 
(MT1-MMP) to degrade the extracellular matrix in order to facilitate migration and 
proliferation. Tissue Inhibitor of Metalloproteinase (TIMP)-2 is the endogenous 
inhibitor of the MMP. Here, we describe a novel and highly effective fusion strategy 
to enhance the delivery of TIMP-2 to MT1-MMP. We can reveal that TIMP-2 fused to 
the haemopexin +/– transmembrane domains of MT1-MMP (two chimeras named 
T2PEX+TM and T2PEX) are able to interact with MT1-MMP on the cell surface as well as 
intracellularly. In the case of T2PEX+TM, there is even a clear sign of MT1-MMP:T2PEX+TM 
aggregation by the side of the nucleus to form aggresomes. In vitro, T2PEX+TM and T2PEX 
suppress the gelatinolytic and invasive abilities of cervical carcinoma (HeLa) and 
HT1080 fibrosarcoma cancer cells significantly better than wild type TIMP-2. In mouse 
xenograft, we further demonstrate that T2PEX diminishes cervical carcinoma growth 
by 85% relative to the control. Collectively, our findings indicate the effectiveness of 
the fusion strategy as a potential targeted approach in cancer inhibition.
INTRODUCTION
Membrane Type 1-Matrix Metalloproteinase (MT1-
MMP, also known as MMP-14) is a zinc-containing 
endoproteinase of the Metzincin superfamily that counts 
among its members the matrix metalloproteinases (MMPs), 
the membrane-anchored adamalysins (ADAMs) as well as 
the soluble ADAMTS proteases with a characteristic type 
I thrombospondin motifs at the C-terminal ends [1–5]. Of 
the twenty five MMPs identified to date, MT1-MMP is 
by far the most prominent due to its pivotal roles in the 
modulation of pericellular proteolysis and cancer cell 
proliferation [5–11]. The substrates of the MMP include an 
impressive range of basement membrane and extracellular 
matrix (ECM) macromolecules such as collagens type I, 
II, and III, laminins, fibronectin, fibrin and the integral 
membrane proteoglycan NG2 [5, 12]. The involvement 
of MT1-MMP in tumourigenesis in fact goes way beyond 
ECM degradation as the MMP is also a versatile sheddase 
that modulates the maturation of the regulatory proteins 
RANKL, MUC1 and PTK1 that are involved in cancer 
migration and dissemination [13–15]. Indeed, there has 
been well-established evidence from clinical studies 
over the years linking elevated MT1-MMP expression 
with poor prognosis in various types of cancers [16–18]. 
Structure-wise, MT1-MMP is a modular protein consisting 
of a pro-domain, a catalytic domain, a haemopexin (PEX)-
like domain followed by a transmembrane (TM) anchor 
and a short cytoplasmic tail. Through the formation of 
homophilic dimers on the cell surface via its haemopexin 
and transmembrane domains, MT1-MMP facilitates pro-
MMP-2 activation and directly promotes tumour cell 
invasion and proliferation [19, 20].
The enzymatic activities of the MMPs, including 
that of MT1-MMP, are regulated by the endogenous 
inhibitors, Tissue Inhibitor of Metalloproteinases (TIMPs). 
There are four human TIMPs (TIMP-1 to -4) and they 
are all small molecules ranging between 20 to 24 kDa in 
molecular masses [21, 22]. TIMPs exert their inhibitory 
functions by inserting the wedge-like “MMP-binding 
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ridge” edges into the catalytic clefts of the MMPs in 1:1 
stoichiometry to hinder the proteases from gaining access 
to the substrates [23–25]. Despite sharing a common 
three-dimensional (3D) structure, the inhibitory activity 
of the TIMPs is highly selective. MT1-MMP, for instance, 
can be inhibited by TIMP-2, -3 and -4 at sub-nanoMolar 
affinity but not TIMP-1 [26]. Among the TIMPs, TIMP-2 
is distinct and clinically important not only because of its 
role as the physiological inhibitor of MT1-MMP but also 
for its part in pro-MMP-2 and -9 activation. By first forming 
a bi-molecular MT1-MMP:TIMP-2 receptor with MT1-
MMP, TIMP-2 has the unique ability to interact with pro-
MMP-2 (or pro-MMP-9) through its C-terminal domain in 
an orientation that would allow the pro-MMP-2 (or -9) for 
further cleavage by an adjacent, TIMP-2-free MT1-MMP 
[27, 28]. The release of a cascade of active gelatinases with 
multiple degradation activities is unfortunately, also a vital 
step required for neo-vascularisation and tumourigenesis 
[29, 30]. This undesirable feature of TIMP-2 has always 
been a deterring factor in its development as a therapeutic 
agent to treat MT1-MMP-related diseases such as cancers. 
In this study, we describe a novel and highly 
effective fusion strategy for the exclusive purpose of MT1-
MMP inhibition. By exploiting the unique predisposition 
of the PEX domain to dimerise on the cell surface [19, 31], 
we devise a warhead-and-missile tactic to target TIMP-2 
to MT1-MMP using a range of soluble and membrane-
anchored PEX-derived C-terminal carriers. We can reveal 
that a TIMP-2 variant named “T2PEX” created by fusion 
with the truncated PEX domain of MT1-MMP is highly 
selective as well as effective in the suppression of cellular 
MT1-MMP activity. Transduction of T2PEX into cervical 
carcinoma cells not only results in a significant reduction 
in the invasiveness of the cells in in vitro settings, but 
also the incidence of tumour development in vivo. We are 
optimistic that the approach presented herein can represent 
the basis of a new strategy in TIMP engineering as well as 
cancer therapy.
RESULTS
Membrane TIMP-2s: design and rationale 
A total of six different TIMP-2 chimeras were 
created in this study out of which three were membrane-
anchored. The TIMPs are: (a) wild type TIMP-2 (T2WT) (b) 
TIMP-2 with a C-terminal V5 and 6x Histidine tag (T2VH) 
(c) TIMP-2 in fusion with the PEX and TM domains 
of MT1-MMP (T2PEX+TM) (d) TIMP-2 fused with the 
truncated PEX domain of MT1-MMP (T2PEX) (e) TIMP-2 
fused to the glycosylphosphatidylinositol (GPI) signal 
peptide of the Reversion Inducing Cysteine Rich Protein 
With Kazal Motifs, i.e. RECK (T2RECK) and lastly, TIMP-2 
fused to the GPI signal peptide of the prion protein (T2Pr). 
The amino acid sequences of the C-terminal carriers are 
listed in Figure 1A. 
Native MT1-MMP forms dimers on the cell 
membrane via homophilic attraction of its PEX and 
TM domains [20]. Transplantation of the two domains 
onto TIMP-2, we hypothesised, would create a chimera 
TIMP (namely T2PEX+TM) that has the potential capacity 
to ensnare MT1-MMP. The soluble TIMP variant T2PEX 
was designed primarily to investigate if the PEX domain 
alone was sufficient to deliver TIMP-2 to MT1-MMP in 
the absence of a TM anchor. T2RECK and T2Pr were in turn 
created with the sole aim of relocating TIMP-2 to the cell 
membrane via GPI anchors. Through anchorage to the 
membrane and thus being in close proximity with MT1-
MMP, it was our hope that the potency of TIMP-2 against 
MT1-MMP could be enhanced as a consequence. 
Translocation of TIMP-2 to cell membrane by 
C-terminal carriers
 Reverse zymography was adopted to monitor TIMP 
localisation at the outset of this project as the technique 
allows the molecular weights as well as the MMP-
inhibitory activity of the chimera TIMPs to be determined 
[32]. Figure 1B is a reverse zymography of the membrane 
extracts and conditioned media of human cervical cancer 
cells (HeLa) stably transduced with the TIMPs. As shown, 
while T2WT and T2VH were entirely soluble, T2PEX+TM, 
T2RECK and T2Pr were sequestered exclusively to the 
membrane fraction, there was no trace of these TIMPs 
in the conditioned media. T2PEX, on the other hand, was 
detected in both the membrane extracts and conditioned 
media. The presence of T2PEX in the membrane extract is a 
finding of particular interest to us as the TIMP should, in 
theory, be capable of forming complexes with MT1-MMP 
via its C-terminal PEX tag despite being a soluble protein. 
The fact that the TIMP was detectable in the membrane 
fraction was the first indication of its ability to bind to the 
target MT1-MMP as hoped. 
The findings confirmed that not only had the TIMPs 
been expressed and folded correctly in the cells, so was 
their localisation. Under non-denaturing condition, the 
molecular masses of the TIMPs were estimated to be 
16 kDa (T2WT), 19 kDa (T2VH), 45 kDa (T2PEX+TM), 42 kDa 
(T2PEX), 19 kDa (T2RECK) and 17 kDa (T2Pr) respectively. 
The estimated molecular weights were slightly lower than 
the calculated molecular masses of 21–55 kDa owing 
to the compactness of the TIMP molecule as a result of 
having six intramolecular disulphide bonds [24]. (More 
data on AAV293 and HT1080 in Supplementary Figure 1).
Co-localisation of T2PEX+TM, T2PEX and T2RECK 
with MT1-MMP on the cell surface as revealed 
by non-permeabilised immunostaining  
We next performed a double immunostaining on 
stably-transduced HeLa cells under non-permeabilising 
condition to ascertain if the TIMPs had indeed been 
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successfully translocated to the cell surface. As shown in 
Figure 2, not only could T2PEX+TM, T2PEX and T2RECK be 
detected as patchy and small punctate granules on the cell 
membrane, the TIMPs also demonstrated clear signs of 
co-localisation with MT1-MMP. In HeLa cells expressing 
T2PEX+TM, the signal of MT1-MMP appeared to be slightly 
higher possibly as a result of MT1-MMP:T2PEX+TM 
complex accumulation on the cell surface. Comparing to 
the other TIMPs, T2Pr was also detectable albeit at a lower 
intensity. Moreover, the TIMP appeared to show a less 
obvious sign of co-localisation with MT1-MMP probably 
because of the lower expression level.
T2PEX+TM and T2PEX induce “mesenchymal to 
amoeboid-like” morphological transition in 
HT1080 cells 
An interesting feature we noticed in HT1080 cells 
stably transduced with T2PEX+TM and to a smaller degree, 
T2PEX, was their heterogeneous size but essentially more 
rounded and amoeba-like appearance (Figure 3A). As 
highlighted in Figure 3B, the cell shape of HT1080 
expressing T2PEX+TM and T2PEX was distinctly different 
from the spindle-shaped control cells (Figure 3B, top 
panel). The change in phenotype observed in T2PEX+TM 
and T2PEX cells was rather similar to the mesenchymal-
to-amoeboid-like morphological transition previously 
documented in proteolytically-disabled HT1080 cells [33]. 
By constraining the proteolytic ability of HT1080 cells 
with a cocktail of protease inhibitors, Wolf and co-workers 
first noticed that HT1080 cells were able to switch from a 
“proteolytically-active mesenchymal type movement” to 
a “non-proteolytic amoeboid movement” as a means of 
escaping abrogation of pericellular proteolysis. The fact that 
T2PEX+TM- and T2PEX-expressing HT1080 cells also assumed 
an amoeboid-like morphology is a putative reflection of the 
proteolytically disabled state of the cells. Interestingly, no cell 
shape change was noticed in HeLa cells similarly transduced 
with the two chimera TIMPs (Figure 3B, lower panel).
Co-localisation of T2PEX+TM and T2PEX with 
intracellular MT1-MMP
 To visualise how the membrane-anchored TIMP-2s 
were localised inside the cells, a double immunostaining 
was subsequently carried out on HeLa cells as described 
above except under permeabilising condition. As shown 
in Figure 4, T2PEX+TM and T2PEX exhibited an intense 
degree of co-localisation with cellular MT1-MMP in the 
cytoplasm and perinuclear regions. In T2PEX+TM-expressing 
cells, masses of T2PEX+TM:MT1-MMP aggregates could be 
detected in areas around the nucleus (Figure 4, highlighted 
by arrowheads). The co-localisation profile of T2PEX 
was slightly different. Instead of forming granule-like 
Figure 1: Amino acid sequences and membrane sequestration of TIMP-2s tagged with different C-terminal carriers 
in stably-transduced HeLa cells. (A) Amino acid sequences for wild type TIMP-2 (T2WT) and the C-terminal carriers VH, PEX+TM, 
PEX, RECK and Pr. (B) Reverse zymography showing distribution of the TIMPs in the membrane fractions and conditioned media of 
stably-transduced HeLa cells. While T2WT and T2VH were entirely soluble, T2PEX could be detected in both the conditioned media as well 
as the membrane extracts. T2PEX+TM, T2RECK and T2Pr, on the contrary, were found exclusively sequestered to the membrane fractions 
(the TIMPs are marked by asterisks *). 
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Figure 2: Co-localisation of membrane-anchored TIMP-2s with MT1-MMP on the cell surface as revealed by non-
permeabilised immunostaining. HeLa cells stably expressing T2WT and T2PEX+TM, T2PEX, T2RECK and T2Pr were subjected to co-
immunostaining with antibodies against MT1-MMP and TIMP-2 under non-permeabilising condition. While the signal of wild type TIMP-
2 (T2WT) was faint and difficult to visualise, T2PEX+TM, T2PEX and T2RECK showed up as more intense punctate granules in clear co-localisation 
with MT1-MMP. In comparison to the other membrane TIMP-2s, T2Pr was lower in expression and thus harder to distinguish from that of 
T2WT (Left: MT1-MMP antibody; Middle: TIMP-2 antibody in conjunction with 4′, 6′-diamidino-2-phenylindole (DAPI) staining; Right: 
merged image).
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aggregates, T2PEX:MT1-MMP complexes were generally 
smaller in size but flaky in appearance. In contrast, the 
co-localisation pattern of the other two membrane TIMP-
2s namely T2RECK and T2Pr was much less pronounced. 
The duo co-localised with MT1-MMP primarily in the 
cytoplasm but also on the cell membrane to a lesser 
extent (highlighted by arrowheads). Overall, the degree 
of brightness observed in T2RECK and T2Pr was far lower 
than those of T2PEX+TM and T2PEX. In comparison with the 
membrane-anchored TIMP-2s, wild type TIMP-2 (T2WT) 
showed only a limited co-localisation with MT1-MMP 
mainly at the perinuclear regions. 
T2PEX+TM interacts with intracellular MT1-MMP 
to end up in the aggresomes
As opposed to T2PEX+TM, the co-localisation pattern 
of T2PEX was limited to the “flaky” phase. At no time could 
we detect granule-like aggregates in the cells. 
HT1080 and HeLa cells display different 
gelatinolysis patterns 
Prior to assessing the inhibitory potency of the 
individual chimera TIMP-2s, we first investigated 
the MT1-MMP activity of our cell lines of choice by 
monitoring their profiles of gelatin degradation on a thin 
layer of fluorescent gelatin substratum. As highlighted 
by Figure 6A, the film on which HT1080 cells were 
cultured was typically marred by distinctive trails 
of dark imprints that in a way, reflect the subcellular 
location in which MT1-MMP was most enzymatically 
active. HeLa cells displayed an entirely different pattern 
of gelatin degradation. Instead of leaving imprints on 
the substratum, the cells were more characteristically 
surrounded by shady halos of gelatin-free zones as 
highlighted by arrowheads the same figure. We further 
immunostained HT1080 cells with an antibody against 
MT1-MMP and matched the subcellular distribution 
Figure 3: T2PEX+TM- and T2PEX-induce mesenchymal to amoeboid-like morphological transition in HT1080 cells. 
(A) Transduction of T2PEX+TM and to a lesser extent, T2PEX into HT1080 induced a morphological change from spindle-shaped to a more 
rounded amoeboid-like phenotype (B) Top panel: Detailed image of the amoeboid-like cell phenotype induced by T2PEX+TM and T2PEX 
expression (highlighted by arrowheads). Lower panel: no shape change was observed in HeLa cells similarly transduced with the TIMPs. 
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of the proteinase to the gelatinolytic imprints left on 
a fluorescent gelatin film. The overlay image (Figure 
6B, 6C) indicates that although MT1-MMP was present 
most abundantly around and under the nucleus as 
well as the lamellipodia, the gelatinolytic activity was 
overwhelmingly concentrated around and beneath the 
perinuclear region.
Membrane TIMP-2s impair the gelatinolytic 
activity of HT1080 and HeLa cells 
We next assessed the inhibitory activity of 
the membrane-anchored TIMP-2s by comparing the 
gelatinolysis pattern of stably-transduced HT1080 
and HeLa cells using the protocol described above. As 
Figure 4: Co-localisation of T2PEX+TM and T2PEX with intracellular MT1-MMP in HeLa cells as revealed by confocal 
microscopy. While T2WT, T2RECK and T2Pr only partially co-localised with MT1-MMP, the co-localisation of T2PEX+TM and T2PEX was 
intense. T2PEX+TM in particular formed aggregates with MT1-MMP in areas around the nucleus (highlighted by arrowheads).
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demonstrated in Figure 6D, HT1080 cells transduced with 
T2WT left a trail of imprints similar in size and intensity 
to those of the empty vector control. In contrast, the 
gelatinolytic activity of all the membrane-anchored TIMP-
2-producing cells were significantly weaker in particular 
T2RECK. Though not as obvious, T2PEX+TM, T2PEX and T2Pr-
expressing cells also displayed a significant reduction 
in activity in comparison with T2WT and the control. 
The broad-range MMP inhibitors batimastat (1 μM) and 
ilomastat (1 μM) were included in the experiment to 
Figure 5: Confocal microscope images showing different form of T2PEX+TM:MT1-MMP aggregates in HeLa cells. 
(A) From nebulous flakes in the cytoplasm (top panel) to granule-like aggregates beside the nucleus (lowest panel), different forms of 
T2PEX+TM:MT1-MMP aggregates could be detected in HeLa cells stably transduced with T2PEX+TM. (B) Top panel: Double immunostaining 
with antibodies against TIMP-2 and tubulin reveals the journey of T2PEX+TM micro-particulates to the centrosome via the microtubule 
transportation network. Lower panel: assembly of T2PEX+TM aggresome at the centrosome as shown by immunostaining with antibodies 
against TIMP-2 and pericentrin, a centrosome marker. The cell nuclei were highlighted by DAPI staining.
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confirm that the gelatin-degradation activity was indeed 
MMP-related.
On the whole, the profile of inhibition observed 
in HeLa is comparable to that of the HT1080. While the 
control and T2WT-expressing HeLa cells were surrounded 
by a zone of shady halos against a green background, 
no such halos existed around the cells that have been 
transduced with T2PEX and T2RECK. On the other hand, 
although smaller and less intense halos were occasionally 
spotted around T2PEX+TM and T2Pr cells, the contrast with 
the background was so weak that they could barely be 
noticed in the majority of the cell population. In all, results 
from the assay corroborated our previous findings on the 
potency of the chimera TIMP-2s on MT1-MMP inhibition. 
Membrane-anchored TIMP-2s have no effect 
on pro-MMP-2, -9 activation and MT1-MMP 
expression
The ensuing question we wanted to address is 
whether membrane-anchored form of TIMP-2s have an 
effect on pro-MMP-2 and -9 activation. Figure 6E contains 
images of zymography gels on which the conditioned media 
of stably-transduced HT1080 and HeLa cells were analysed. 
In HT1080 as well as HeLa, an almost indistinguishable 
pattern of MMP-2 and -9 processing was observed among 
the controls and all the TIMP-expressing cells. 
To examine if the membrane-anchored TIMP-2s had 
impacted on MT1-MMP expression, the cell lysates were 
subjected to western blot analysis with an antibody against 
the catalytic domain of MT1-MMP. In HT1080, only two 
major forms of MT1-MMP were detected, i.e. a 60 kDa 
variant and a smaller species of approximately 58 kDa 
(Figure 6E, left). Apart from a slight reduction in the 
60 kDa variant in T2Pr, there was no indication to suggest 
that MT1-MMP production has been considerably altered 
among the cells. In HeLa, the two MT1-MMP variants 
detected were of 60 kDa and 63 kDa in mass (Figure 6E, 
right). Again, no substantial difference in MT1-MMP 
expression was noticed among the samples. The results 
thus indicated to us that membrane TIMP-2s had no 
significant impact on either pro-MMP-2/-9 activation or 
MT1-MMP production.   
Impaired migration of T2PEX+TM-, T2PEX- and 
T2RECK-expressing HT1080 and HeLa cells in 
Transwell® migration assay
A Transwell® migration assay was set up to evaluate 
if the migratory behaviour of HT1080 and HeLa cells had 
been affected by the membrane-anchored TIMP-2s. The 
results of the assay are summarised in Figure 7. In both 
cell lines, T2PEX+TM emerged as the most effective TIMP 
in the suppression of cell migration (*p < 0.01 compared 
to empty vector control and T2WT) closely followed by 
T2RECK and T2PEX. T2Pr fared worst in this assay, the TIMP 
had a negligible impact on cell motility in both HT1080 
and HeLa cells. Of noteworthy is the near-identical profile 
of inhibition displayed by the two cell lines.    
Suppression of cervical cancer (HeLa) growth by 
T2PEX+TM and T2PEX in vivo
The inhibitory activities of the TIMPs were further 
evaluated in vivo by subcutaneous implantation of all 
the TIMP-producing HeLa cells into NOD/SCID mice. 
Figure 8A summarises the results of the study on day-30 
when the experiment was concluded. As shown, all the 
10 inoculums in the control (empty vector) group grew 
to an average volume of 155 mm3 over the course of 
30 days. In comparison, tumours from the TIMP groups 
were substantially smaller. The growth curve contained in 
Figure 8B indicates that, while primary tumours started 
to emerge within 10 days of implantation in the control 
and T2Pr groups, there was barely any evidence of tumour 
formation in the remaining mice. Rapid growth occurred 
between day-10 and 20 in the control, T2Pr as well as 
T2RECK groups with tumours in these mice showing an 
accelerated expansion in volume. Conversely, only 
small tumours appeared in the T2WT, T2PEX+TM and T2PEX 
mice by the end of day-20. Tumour volumes continued 
to increase rapidly in the control, T2Pr and T2RECK mice 
between day-20 to 30 when the experiment reached a 
humane endpoint. In the same time, mice in the T2WT 
group also recorded a surge in growth rate. T2PEX+TM and 
T2PEX tumours, in comparison, were still developing 
at a relatively modest pace by the time the experiment 
was terminated. In fact, the estimated average tumour 
volumes of the two (37 mm3) was only 24% of that of the 
control (155 mm3) (*p < 0.001).
Post-mortem analysis carried out on day-30 
confirmed that, without exception, the average tumour 
masses of the TIMP groups were all significantly smaller 
than that of the control group (*p < 0.05). Figure 8C is a 
scattered chart showing the individual masses for all the 
tumours in this study. Among the TIMPs, the performance 
of T2PEX+TM and T2PEX were the most impressive. Not 
only did the pair have the lowest tumour development 
incidence; only 8 of the 13 (61.5%) implantations in the 
T2PEX+TM group and 10 of the 14 (71.4%) in the T2PEX 
group developed into tumours by the end of this study, the 
average tumour masses of the two (25.6 mg for T2PEX +TM; 
16.6 mg for T2PEX) were only a fraction of those of the 
control mice (mean tumour mass = 107.6 mg) (*p < 0.001). 
Comparing to T2WT, T2PEX was also a more effective 
tumour suppressor (*p < 0.1). 
On the other hand, even though T2RECK and T2Pr fared 
considerably better than the control group in this study, 
their performance was less than satisfactory in comparison 
with that of T2WT.  With average tumour masses of 55.6 mg 
and 54.1 mg, the duo were indeed poorer growth inhibitors 
than T2WT (mean tumour mass = 34.2 mg) (*p < 0.1). 
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DISCUSSION
Given its pivotal role in tumour dissemination, MT1-
MMP has been the subject of a variety of intervention 
strategies over the years. Therapeutic approaches ranging 
from small molecule inhibitors (MMPI), blocking 
antibodies to recombinant TIMPs, to name a few, are 
among the tactics that have been extensively explored 
and pursued [34–38]. While the MMPI have suffered a 
setback in advanced clinical trials due to unforeseen 
Figure 6: Membrane-anchored TIMP-2s inhibit gelatin degradation by HT1080 and HeLa cells. (A) While HT1080 
cells typically leave a criss-cross trail of imprints along their tracks of movement, the gelatinolysis activity of HeLa cells appears as clear 
pericellular halos against a green background (marked by arrowheads). (B)  Left: imprints left by HT1080 cells on fluorescent gelatin film 
after an overnight incubation. Right: subcellular localisation of MT1-MMP as revealed by immunostaining. Middle: DAPI staining of the 
nuclei. (C)  Magnified images demonstrating how the gelatinolytic activity of HT1080 (left) correlates with the subcellular distribution of 
MT1-MMP (middle). Superimposition of the images shows that the gelatinolysis activity of HT1080 was largely concentrated around and 
beneath the nucleus (right). (D) In both HT1080 and HeLa cells, membrane TIMP-2-expressing cells had significantly smaller imprints/
halos in comparison to the control and T2WT-expressing cells. (E) no significant changes in MMP-2, -9 and MT1-MMP levels were detected 
among membrane TIMP-2-expressing cells as shown by zymography and western blot. 
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toxicity-related side effects, progress with the TIMPs has 
been slow [39]. The main reason, from a structural point 
of view, comes from the catalytic domains of the MMP. 
Owing to a general resemblance in the 3D structure of the 
catalytic domains of the Metzincins, it has so far not been 
possible to design a TIMP to be exclusively MT1-MMP-
specific. The protein engineering work in this study differs 
from previous mutagenesis endeavours as our current 
approach aims to improve the efficiency of TIMP-2 not 
by mutating the TIMP as customarily performed but by 
redesigning its mode of delivery. 
Collectively, evidence from reverse zymography on 
membrane extracts and non-permeabilised immunostaining 
confirm that the three carriers PEX+TM, RECK and Prion 
have all fulfilled their missions of providing anchorage in 
the way that we had anticipated. The fourth carrier PEX is 
not intended to be a membrane anchor. Instead, the carrier 
was designed to entice and ensnare MT1-MMP to form 
a homophilic complex with TIMP-2. The fact that T2PEX 
is partially partitioned to the membrane and its intense 
co-localisation with MT1-MMP inside the cell as well as 
on the cell surface as revealed by immunofluorescence 
corroborates our belief that the carrier has also achieved 
its purpose of complexing with MT1-MMP. The first sign 
indicating the effectiveness of the PEX carriers comes 
from the mesenchymal-to-amoeboid-like morphological 
conversion observed in HT1080 cells. Transduction of the 
TIMPs into HT1080 is, in effect, very similar to that of 
adding a cocktail of MMP inhibitors as described by Wolf 
and colleagues [33]. The proteolytically attenuated state 
of T2PEX+TM and T2PEX-expressing cells, as evidenced by 
their inability to digest gelatin substratum and diminished 
motility across Transwell® chambers, further validates the 
inhibitory efficacy of the TIMPs.    
In all, findings from reverse zymography, cell 
morphology, gelatinolytic and co-localisation studies all 
lead to the conclusion that T2PEX+TM has been processed to 
a membrane-anchored form recognisable by its intended 
target MT1-MMP. Through interactions at the TIMP, PEX 
and perhaps the TM domains, T2PEX+TM forms a membrane-
Figure 7: T2PEX+TM, T2PEX and T2RECK suppress HT1080 and HeLa cell migration in Transwell® invasion assays. In both 
cell types, T2PEX+TM-expressing cells demonstrated the slowest migration rate closely followed by T2RECK and T2PEX (*p < 0.01 compared to 
empty vector control. The readings reflect the average of two technical repeats). Y-axis: number of cells that had traversed the membrane 
after an overnight incubation.
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bound and yet non-functional protease:inhibitor complex 
with MT1-MMP that ultimately ends up in the recycling 
pathway. Much unexpected, however, is its exceptional 
ability to interact and co-aggregate with the protease 
inside the cells. Aggresome normally forms when the 
amount of intracellular misfolded proteins exceeds the 
clearance capacity of the chaperone-mediated refolding 
and proteasomal degradation systems [40]. Given that 
TIMP:MT1-MMP aggresomes are present only in 
T2PEX+TM-producing cells and not T2PEX, the uniqueness 
of T2PEX+TM can therefore be attributable to the TM 
anchor. The fact that co-aggregation with MT1-MMP 
only occurred in T2PEX+TM may also reflect the more 
demanding recycling processes required for misfolded 
membrane proteins as opposed to soluble cytoplasmic 
ones. The efficacy of T2PEX+TM and T2PEX in abrogating 
tumour development in vivo, we surmise, is due to 
their ability to prevent MT1-MMP-driven cleavage and 
remodelling of the cell matrices by the implanted cancer 
cells. A precondition for MT1-MMP to be a tumour-
derived growth factor is pericellular proteolysis of the 
ECM [41]. Deprived of the capability to proteolytically 
change the extracellular matrices, T2PEX+TM- and T2PEX-
expressing HeLa cells are therefore trapped in a compact, 
spherical configuration incapable of undergoing changes 
in cell shape or cytoskeletal reorganization required for 
3D growth.
Besides an improvement in delivery, our current 
strategy may also offers several clear advantages over 
the conventional way of TIMP engineering. First and 
Figure 8: T2PEX+TM and T2PEX suppress cervical carcinoma cell growth in vivo. (A) While all the inoculums in the empty vector 
control and T2Pr groups developed into tumours (100%), much lower tumour development incidence were recorded in T2PEX+TM (8 out of 13; 
61.5%) and T2PEX (10 out of 14; 71.4%) mice. Dotted circles indicate inoculums that failed to become tumours. (B) Tumour grow curves 
measured at different time points over a 30-day period. Plotted data represent the mean for each TIMP group. (C) Scattered chart showing 
individual tumour masses on day-30 when the experiment was concluded (grey bars indicate the mean for each group). On average, the 
tumour masses for T2PEX+TM (25.6 mg) and T2PEX (16.6 mg) mice were significantly smaller than the control (107.6 mg) group (*p < 0.001). 
The study has been performed twice in different scale to confirm the reproducibility of the results.
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foremost, by immobilising TIMP-2 to the cell membrane, 
no secretion of the inhibitor to the media was permitted. 
Wastage through discharge to the conditioned media is 
therefore kept to a minimum. Secondly, our strategy may 
have also considerably enhanced the affinity of TIMP-2 
for MT1-MMP. By its own, the association constant 
(Ki
app) of TIMP-2 for the catalytic domain of MT1-MMP 
is 1.3 nM [26]. The affinity of the PEX-tagged T2PEX+TM 
and T2PEX are likely to be even higher due to an additional 
interaction site in their C-terminal domains [20, 31]. 
Thirdly, our approach has overcome the shortcoming 
of TIMP-2 as a pro-MMP-2 activator, a defect that has 
thus far compromised its prospect as a therapeutic agent 
[28, 42, 43]. Due to the bulky and restrained nature of 
their C-terminal domains, our modelling exercise suggests 
that membrane-anchored forms of TIMP-2 are sterically-
hindered from forming a trimolecular complex with MT1-
MMP and pro-MMP-2 that could lead to subsequent 
pro-MMP-2 potentiation. Furthermore, embedment to 
the membrane might also be beneficial as a means of 
reducing TIMP-2’s exposure to circulating proteases in 
the extracellular compartment.
In all, we have provided concrete evidence to 
demonstrate the effectiveness of fusing TIMP-2 with the 
PEX domain as a means of delivering the TIMP for MT1-
MMP inhibition. T2PEX+TM and T2PEX have both achieved 
the goal of interacting with MT1-MMP in the cell and the 
process has led to attenuation of the protease both in vitro 
and in vivo. The findings further underscore the prospect 
of MT1-MMP inhibition as a viable option to block cancer 
proliferation. We are currently in the process of producing 
and testing the therapeutic efficacy of recombinant 
T2PEX protein in mice. The results will be submitted for 
publication upon conclusion of the project in the near 
future. It is our hope that the results would form the basis 
of a novel and targeted approach in cancer inhibition. 
MATERIALS AND METHODS
Materials  
All reagents, restriction enzymes and protein 
extraction kit were products of ThermoScientific USA 
unless otherwise stated. Antibodies against TIMP-2 (R&D 
Systems; MAB971) and MT1-MMP (Abcam; Ab72685 
against activated MT1-MMP from cleavage adjacent to 
Tyr112) were purchased separately from R&D Systems, 
MN and Abcam, MA, USA. Pwo DNA polymerase and 
ProteoExtract® Native Membrane Protein Extraction Kit 
were products of Merck, Darmstadt, Germany. TIMP-1 and 
-2 proteins were produced in house using Sf-9 insect cell as 
described in our previous paper [44].  AAV293, HeLa and 
HT1080 cell lines were purchased from the Shanghai Cell 
Bank, Chinese Academy of Science while Lenti-X 293T 
cells were imported directly from Takara® BIO Inc., CA 
without further authentication. Non-obese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice were 
ordered through GenePharma Co. Ltd, Biobay, Suzhou 
Industrial Park, Jiangsu, China. All the experiments in this 
study have been performed independently at least twice to 
confirm the reproducibility of the findings. 
Construction of membrane-anchored TIMP-2s 
Short carriers consisting of forty amino acid residues 
or fewer were introduced directly to the C-terminus of 
TIMP-2 by overlapping polymerase chain reaction (PCR) 
with reverse primers bearing the corresponding sequences. 
For longer carriers such as PEX +/– TM domains, the DNA 
fragments encoding for TIMP-2 and MT1-MMP PEX 
domain were first amplified as independent fragments by 
PCR before ligation into pcDNA3.1 vector. All the clones 
generated in this study had been sequenced in both strands 
to confirm that no unwanted mutation had been introduced 
into the cDNAs during PCR and cloning processes. 
Stable transfection using Lentivirus 
Lentivirus used for infecting HT1080 and HeLa 
cells were generated with Lenti-X Packaging Single 
Shots® system in Lenti-X 293T cells following the 
recommended procedures by Takara® BIO Inc. Upon 
transduction, selection of cells was performed by adding 
1 μg/mL of puromycin to the culture media until stable 
cell lines were obtained, usually after 2 weeks of culture.
Membrane protein extraction 
Briefly, TIMP-2-expressing cells were first 
dislodged from 6-well culture plates and washed 
twice with ice-cold 1× phosphate buffer saline (PBS) 
supplemented with 5 mM EDTA before extraction with 
200 μL buffer I (soluble proteins) and 100 μL buffer 
II (membrane proteins) at 4°C as per manufacturer’s 
instructions. Extracted membrane proteins were stored in 
50 μL aliquots at –80°C until required for analysis.
Reverse zymography 
Reverse zymography was carried out in 11% non-
denaturing SDS-PAGE incorporated with 0.3% gelatin 
and MMP-2 essentially as described [32]. Following 
electrophoresis, gels were washed three times in 2.5% 
Triton X-100 solution followed by a further three washes 
in 2.5% Triton X-100 in 50 mM Tris HCl, pH 7.5. After 
a brief rinse in running water, the gels were incubated 
overnight at 37°C in an activation buffer (50 mM Tris HCl 
pH7.5, 50 mM NaCl, 10 mM CaCl2 and 10 μM ZnCl2) 
before staining with 0.3% Coomassie Blue in 20% v/v 
methanol, 1% acetic acid in distilled water.
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Transwell® migration assay 
For Transwell® assay, 5 × 104 cells were seeded 
in duplicate on the upper layer of Transwell® Permeable 
Support inserts (8 μm pores) in serum-free DMEM while 
the outer compartments (12-well plate) were filled with 
DMEM supplemented with 5% fetal calf serum (FCS). 
Following overnight incubation at 37°C, the cells that 
had traversed the insert was fixed, permeabilised with 4% 
formaldehyde/methanol and stained with Giemsa dye for 
15 minutes. The number of migrated cells were counted 
from three different fields per-Transwell® and the results 
are expressed as the average of two technical repeats. The 
experiment had also been repeated twice at different cell 
density (10 and 15 × 104 cells/Transwell®) to ensure the 
reproducibility of the profile of migration.
Immunofluorescence
For immunofluorescence under permeabilising 
condition, cells cultured in Nunc® chamber slides were 
first treated with 4% formaldehyde in PBS for 5 minutes 
followed by blocking for 2 hours in PBS containing 5% 
BSA and 0.3% TX-100 before incubation in primary 
antibodies (1:100 in dilution buffer containing 1% BSA, 
0.3% TX-100 in PBS) at 4°C overnight. Following a 
15-minute wash with PBS, Alexa Fluor® 488 (or 555) anti-
mouse and/or anti-rabbit fluorophore-conjugated secondary 
antibodies (1:1,000 in the same dilution buffer) were added 
to the cells for 2 hours before the chamber slides were 
washed and mounted in ProLong® Antifade reagent and 
examined under a Nikon Eclipse Ti confocal microscope. 
The same experimental procedure was used for non-
permeabilising immunofluorescence except no TX-100 
was added to the blocking and antibody dilution buffers.
Gelatin degradation assay
Approximately 500 cells were seeded in Nunc® Lab-
Tek II Chamber Slides® pre-coated with porcine Oregon 
Green® 488-conjugated gelatin (0.5 mg/mL). Following 
overnight incubation at 37°C, the cells were fixed in 4% 
paraformaldehyde and mounted in ProLong® Antifade 
reagent before examination with a Nikon Eclipse Ni 
inverted fluorescent microscope. 
Tumour development study in NOD/SCID mice 
All animal experiments were conducted in 
GenePharma Co. Ltd, Biobay, Suzhou Industrial Park, 
China (licenced by Jiangsu Provincial Government: 
Licence number SYXK (Su) 2014–0054) in strict 
accordance to the protocols outlined in the National 
Guidance for Animal Care, China with respect to 
husbandry, veterinary care and experimental procedures 
throughout the entire length of the project. Immediately 
before injection, HeLa cells were trypsinised, washed 
twice with PBS and re-suspended to yield 1 × 106 cells/mL 
in cold DMEM without FCS. Suspended cells (5 × 105) 
were delivered by subcutaneous injection into the left 
and right flanks of 6-week-old female NOD/SCID mice, 
where n varied between 10 and 14 per group. Mice were 
monitored for tumour formation over 30 days with digital 
callipers. Tumour volume was determined with the 
formula: Volume = Length x (Width)2 x π/6, where the 
width is the smaller of the two perpendicular diameters. 
Abbreviations 
GPI, glycosylphosphatidylinositol; MMP, Matrix 
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